Biocept, Inc. (BIOC) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET
Company Participants
Bruce Voss - Lippert/Heilshorn & Associates
Michael Nall - CEO, President & Director
Timothy Kennedy - CFO, SVP, Operations & Corporate Secretary
Michael Dugan - SVP, Chief Medical Officer & Medical Director
Conference Call Participants
Jason McCarthy - Maxim Group
Sally Yanchus - Brookline Capital Markets
Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Biocept Third Quarter 2020 Financial Results Conference Call. [Operator Instructions]. As a reminder, this conference call is being recorded today, November 12, 2020.
I'd now like to turn the call over to Bruce Voss. Please go ahead.
Bruce Voss
This is Bruce Voss with LHA. Thank you all for participating in today's conference call. Joining me from Biocept are Michael Nall, President and Chief Executive Officer; Tim Kennedy, Senior Vice President of Operations and Chief Financial Officer; and Dr. Michael Dugan, Senior Vice President, Chief Medical Officer and Medical Director.
During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements include all statements that are not historical facts and generally can be identified by terms such as anticipates, estimates, believes, could, expects, intends, may, plans, potential, predicts, projects, should, will, would, or the negative of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those statements as well as performance or achievements that are implied by the forward-looking statements.
In particular, there is significant uncertainty about the duration and contemplated impact of the COVID-19 pandemic. This means results could change at any time, and the contemplated impact of COVID-19 on Biocept's operations, financial results and outlook
- Read more current BIOCQ analysis and news
- View all earnings call transcripts